Groww Logo
Home>IPO>Glenmark Life Sciences Ltd.

Glenmark Life Sciences IPO

Glenmark Life Sciences Ltd.

₹13,900 /20 sharesMinimum Investment

Glenmark Life Sciences IPO Details

Bidding DatesMin. InvestmentLot SizePrice Range
27 Jul '21 - 29 Jul '21₹13,90020₹695 - ₹720
Issue SizeIPO Doc
1513.60Cr
RHP PDF

Subscription Status As on 29 Jul '21, 5:00 PM

  • Retail Individual Investor
    14.63x
  • Non-Institutional Investor
    122.54x
  • Qualified Institutional Buyers
    36.97x

About Glenmark Life Sciences

Glenmark Life Sciences Ltd., a subsidiary of Glenmark Pharmaceuticals Ltd., is a leading developer and manufacturer of s
Parent Organisation
Glenmark Life Sciences Ltd.
Founded
2011
Managing Director
Yasir Rawjee
Glenmark Life Sciences IPO review - Glenmark Life Sciences IPO details, business, financials

Strengths & Risks

  • Leading developer and manufacturer of select high value, non-commoditized APIs in chronic therapeutic areas
  • Strong relationships with leading global generic pharmaceutical companies
  • Quality-focused and has compliant manufacturing and R&D infrastructure
  • Focused on sustainability in its operations through meaningful interventions in environment management, safety initiatives in its operations, and the occupational health of its workforce.
  • Glenmark strives to achieve cost leadership across many of its products through the careful application of operations initiatives, sourcing initiatives, and R&D initiatives
  • Experienced Promoters with a strong management team
  • Regulatory action due to a manufacturing or quality control problem
  • Dependency on a limited number of key customers for a significant portion of its revenues
  • Generates a significant portion of its total revenue from its API business from the sale of products in a limited number of principal therapeutic categories
  • Manufacturing and R&D facilities are located in two states and any disruption in these states can cause manufacturing to stop
  • Delay, interruption, or reduction in the supply of raw materials can harm operations
  • Impact of COVID-19
  • Significant working capital requirements for its manufacturing operations and development of new products
  • The brand name ‘Glenmark’ and the trademarks for the name ‘Glenmark Life Sciences’ and logo are registered in the name of the promoter of the company
  • Impact of pricing pressure from customers on gross margin, profitability and the company’s ability to increase the prices
  • The company has to obtain and maintain a number of statutory and regulatory licenses, permits and approvals for carrying out business including consents to establish and operate under environmental laws
  • Exposure to counterparty credit risk
  • Inability to accurately forecast demand for its products and manage inventory accordingly

Financials

*All values are in Rs. Cr
No Graph Data To Display
ⓒ 2016-2022 Groww. All rights reserved, Built with in India
MOST POPULAR ON GROWWVERSION - 2.3.7
STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
MUTUAL FUNDS COMPANIES:  ICICI PRUDENTIAL |  HDFC |  NIPPON INDIA |  ADITYA BIRLA SUN LIFE |  SBI |  UTI |  FRANKLIN TEMPLETON |  KOTAK MAHINDRA |  IDFC |  DSP |  AXIS |  TATA |  L&T |  SUNDARAM |  PGIM |  INVESCO |  LIC |  JM FINANCIAL |  BARODA PIONEER |  CANARA ROBECO |  HSBC |  IDBI |  INDIABULLS |  MOTILAL OSWAL |  BNP PARIBAS |  MIRAE ASSET |  PRINCIPAL |  BOI AXA |  UNION KBC |  TAURUS |  EDELWEISS |  NAVI |  MAHINDRA |  QUANTUM |  PPFAS |  IIFL |  Quant |  SHRIRAM |  SAHARA |  ITI

ABOUT GROWW